← Eichor
Condition: Nafld And Nash Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Nafld And Nash

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
Phase 2 · 1 location(s) · Fundació Institut de Recerca de l'Hospital de la Santa Creu · NCT06599918Bicalutamide Therapy in Young Women With NAFLD and PCOS
Phase 1 · 1 location(s) · University of California, San Francisco · NCT05979389Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
Phase N/A · 1 location(s) · German Diabetes Center · NCT05046483Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Diseas
Phase 2 · 1 location(s) · AB Biotics, SA · NCT07193927Comorbidities Resolution After MGB Surgery and Change in Body Composition
Phase N/A · 1 location(s) · All India Institute of Medical Sciences, Bhubaneswar · NCT06015620A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Phase 3 · 317 location(s) · 89bio, Inc. · NCT06419374Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Non
NA · 3 location(s) · State Key Laboratory of Subhealth Intervention Technology · NCT07083336Implementing Food Referrals for Equity and Sustained Health
Phase 2 · 2 location(s) · University of California, San Diego · NCT06661538Androgens and NAFLD Longitudinal Cohort Study
Phase N/A · 2 location(s) · University of California, San Francisco · NCT06124261Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
Phase N/A · 2 location(s) · Brigham and Women's Hospital · NCT05728697InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT05463796Prevalence of NAFLD in T1DM Patients
NA · 1 location(s) · Ziekenhuis Oost-Limburg · NCT06445361Effect of Timed-Restricted Eating on Metabolic Health
NA · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT06061042European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
Phase N/A · 3 location(s) · Cambridge University Hospitals NHS Foundation Trust · NCT04190849Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Phase 4 · 1 location(s) · Getz Pharma · NCT05644717Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Phase 2 · 1 location(s) · Tanta University · NCT06863376Characterization of the Intrahepatic Inflammatory Microenvironment in Patients With Non-alcoholic Steatohepatitis
NA · 1 location(s) · Hospices Civils de Lyon · NCT06152250Effects of VLCKD in Metabolic Syndrome
NA · 1 location(s) · Azienda Ospedaliero Universitaria Maggiore della Carita · NCT05275608Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
NA · 1 location(s) · Maja Thiele · NCT03308916Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Phase 2 · 24 location(s) · Can-Fite BioPharma · NCT04697810Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Phase 2 · 13 location(s) · National Institute of Diabetes and Digestive and Kidney Dise · NCT05832229Evaluation of Gut Permeability in Patients Affected by Obesity and NAFLD: Influence of Ketogenic Diet.
NA · 1 location(s) · Azienda Ospedaliera Specializzata in Gastroenterologia Saver · NCT05477212A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) In
Phase 2 · 62 location(s) · Eccogene · NCT07288138PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT04371042Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
NA · 1 location(s) · Valbiotis · NCT06704321A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Phase 3 · 361 location(s) · 89bio, Inc. · NCT06318169The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults
NA · 1 location(s) · Fujian Provincial Hospital · NCT06717828Digoxin In NASH (CODIN)
Phase 2 · 2 location(s) · Yale University · NCT06588699Fructose and Liver Diseases in Youth: Help Them FLY
NA · 1 location(s) · University of Alberta · NCT05528471A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Phase 1 · 1 location(s) · 1Globe Health Institute · NCT06694935
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.